GGHC
DYN icon

Gilder Gagnon Howe & Co’s Dyne Therapeutics DYN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,546
Closed -$619K – 256
2024
Q2 		$619K Buy
+17,546
New +$510K 0.01% 221

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Gilder Gagnon Howe & Co's DYN Position: Q3 2024 in Review

Gilder Gagnon Howe & Co sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 17,546 shares — an estimated $619K sold.

Gilder Gagnon Howe & Co first reported a position in DYN in Q2 2024 and held it in 1 quarter. The position peaked at $619K in Q2 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Gilder Gagnon Howe & Co reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 17,546 Dyne Therapeutics shares in Q3 2024, an estimated $619K.
  • Gilder Gagnon Howe & Co first reported a position in Dyne Therapeutics in Q2 2024 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Dyne Therapeutics position peaked at $619K in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2024, filed 14 Nov 2024.